Relevant publications HEIM

  • Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E,
    McClue S, Vanderkerken K and De Bruyne E. The role of DNA damage and repair
    in decitabine-mediated apoptosis in multiple myeloma. Oncotarget, 2014; 5:
    prepublication.
  • Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M,
    Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T,
    Elewaut D, Vanderkerken K and Menu E, Preclinical evaluation of invariant
    natural killer T-cells in the 5T33 multiple myeloma model, PLOS1, 2013 May
    31;8(5)
  • Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.
    Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.
    PLoS One. 2013 Nov 6;8(11)
  • Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33
    multiple myeloma model. Leukemia, 26(6), 1436-9, 2012. Van Valckenborgh E,
    Matsui W, Agarwal P, Lub S, Xu D, De Bruyne E, Menu E, Empsen C, van
    Grunsven L, Agarwal J, Wang Q, Jernberg-Wiklund H, Vanderkerken K.

 

 

 

 

 

 

 

 

 

 

Comments are closed.